Today, 25th April, marks the anniversary of the completion of the human genome project in 2003 and the discovery of the double helix in 1953. As we celebrate DNA Day, our recently appointed CEO, Simon Davis, reflects on how much progress has been made in genomics since then and how that science has enabled Informed Genomics to help clinicians diagnose cancers earlier, personalise treatments and improve patient outcomes.
1. What are your thoughts on the pace and scale of advances in genomic research and technology since these early science milestones?
Genomics has always been an incredibly exciting area of research with high expectations of how it will transform the way we prevent, diagnose and treat diseases. But I don’t think that 21 years ago, when the human genome project was completed, anyone could have imagined how fast that progress was going to be made, particularly in cancer.
Understanding DNA and using genetic markers to make diagnosis and treatment precise is at the heart of our business and we’re so proud to be part of an industry that is translating these advances in science into benefits for patients.
2. Three months into role, what have been your highlights?
In February, we announced that we would be part of a programme from NHS England improving cancer diagnosis in tens of thousands of people with Jewish ancestry who are more likely to carry a genetic fault that can increase the risk of developing some cancers. This was a real highlight for me because it demonstrates clearly how private and public organisations can work together to make a huge difference for communities.
Having previously been Informed Genomics’ Commercial Director, I knew the team well, but it’s also been a highlight having a clearer overview of how dedicated everyone is to quality and improving the lives of patients.
3. What makes you most excited about leading Informed Genomics?
Our business spans hereditary cancer services, translational research, our recently launched GALEAS Bladder cancer service and Research Use Only (RUO) services. It’s this breadth of services, combined with our varied and global customer base, that make Informed Genomics such an interesting company to lead.
4. What are your plans for the future?
We’ve had significant recognition recently of our pioneering sequencing technology, which has added to our strong momentum, so my focus is working with new and exciting partners that could make a huge impact for patients in the near future.
